{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:17:05Z","timestamp":1783484225941,"version":"3.55.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AMRF","award":["MN-2024"],"award-info":[{"award-number":["MN-2024"]}]},{"DOI":"10.13039\/100012128","name":"Austin Medical Research Foundation","doi-asserted-by":"publisher","award":["HH-2025"],"award-info":[{"award-number":["HH-2025"]}],"id":[{"id":"10.13039\/100012128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02923-y","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:23:03Z","timestamp":1778764983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The interplay between p21-activated kinases and tumour-infiltrating dendritic cells and T cells and its implication in pancreatic cancer immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Rui","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Nikfarjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"1","key":"2923_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2923_CR2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ijms18071338","volume":"18","author":"A Adamska","year":"2017","unstructured":"Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18(7):1338. https:\/\/doi.org\/10.3390\/ijms18071338.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2923_CR3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S1470-2045(13)70388-7","volume":"14","author":"WC Liao","year":"2013","unstructured":"Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(11):1095\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(13)70388-7.","journal-title":"Lancet Oncol"},{"key":"2923_CR4","doi-asserted-by":"publisher","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology. 2022;163(2). https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056.","DOI":"10.1053\/j.gastro.2022.03.056"},{"issue":"11","key":"2923_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones RP, Psarelli EE, Jackson R, et al. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg. 2019;154(11):1038\u201348. https:\/\/doi.org\/10.1001\/jamasurg.2019.3337.","journal-title":"JAMA Surg"},{"issue":"12","key":"2923_CR6","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/bjs.11295","volume":"106","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Mihaljevic AL, Probst P, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106(12):1590\u2013601. https:\/\/doi.org\/10.1002\/bjs.11295.","journal-title":"Br J Surg"},{"issue":"1","key":"2923_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev.pathmechdis.3.121806.154305","volume":"3","author":"A Maitra","year":"2008","unstructured":"Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol Mech Dis. 2008;3(1):157\u201388.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2923_CR8","doi-asserted-by":"publisher","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2023;34(11). https:\/\/doi.org\/10.1016\/j.annonc.2023.08.009.","DOI":"10.1016\/j.annonc.2023.08.009"},{"issue":"7963","key":"2923_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"1","key":"2923_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9(1):112\u201321.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2923_CR11","doi-asserted-by":"publisher","first-page":"100334","DOI":"10.1016\/j.esmoop.2021.100334","volume":"7","author":"R Zhong","year":"2022","unstructured":"Zhong R, Ling X, Cao S, et al. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC\/LuCa) combined with carboplatin\/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. ESMO Open. 2022;7(1):100334.","journal-title":"ESMO Open"},{"issue":"5","key":"2923_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"2923_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12935-018-0585-0","volume":"18","author":"A Deicher","year":"2018","unstructured":"Deicher A, Andersson R, Tingstedt B, Lindell G, Bauden M, Ansari D. Targeting dendritic cells in pancreatic ductal adenocarcinoma. Cancer Cell Int. 2018;18(1):85.","journal-title":"Cancer Cell Int"},{"issue":"26","key":"2923_CR14","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.23.02585","volume":"42","author":"FR Van \u2018T Land","year":"2024","unstructured":"Van \u2018T Land FR, Willemsen M, Bezemer K, et al. Dendritic cell\u2013based immunotherapy in patients with resected pancreatic cancer. J Clin Oncol. 2024;42(26):3083\u201393. https:\/\/doi.org\/10.1200\/JCO.23.02585.","journal-title":"J Clin Oncol"},{"issue":"Pt 3","key":"2923_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1042\/bj2790609","volume":"279","author":"RJ Grand","year":"1991","unstructured":"Grand RJ, Owen D. The biochemistry of ras p21. Biochem J. 1991;279(Pt 3):609.","journal-title":"Biochem J"},{"issue":"1","key":"2923_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"1","key":"2923_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. Dendritic cells revisited. Annu Rev Immunol. 2021;39(1):131\u201366.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2923_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo I, Adan-Barrientos I, Gal\u00e1n M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21(4):257\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR19","doi-asserted-by":"crossref","unstructured":"Duluc D, Sisirak V. Origin, phenotype, and function of mouse dendritic cell subsets. Methods in molecular biology (Clifton, N.J.) vol. 2618 .2023:3\u201316.","DOI":"10.1007\/978-1-0716-2938-3_1"},{"issue":"11","key":"2923_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/eji.202149632","volume":"52","author":"E Segura","year":"2022","unstructured":"Segura E. Human dendritic cell subsets: an updated view of their ontogeny and functional specialization. Eur J Immunol. 2022;52(11):1759\u201367.","journal-title":"Eur J Immunol"},{"issue":"5","key":"2923_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20(5):432\u201347.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"2923_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde S, Krisnawan VE, Herzog BH, et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020;37(3):289-307.e9. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.008.","journal-title":"Cancer Cell"},{"issue":"5","key":"2923_CR23","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/cancers14051216","volume":"14","author":"I Plesca","year":"2022","unstructured":"Plesca I, Bene\u0161ov\u00e1 I, Beer C, et al. Clinical significance of tumor-infiltrating conventional and plasmacytoid dendritic cells in pancreatic ductal adenocarcinoma. Cancers. 2022;14(5):1216.","journal-title":"Cancers"},{"issue":"9","key":"2923_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/cac2.12596","volume":"44","author":"J Chen","year":"2024","unstructured":"Chen J, Duan Y, Che J, Zhu J. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy. Cancer Commun. 2024;44(9):1047\u201370.","journal-title":"Cancer Commun"},{"key":"2923_CR25","doi-asserted-by":"publisher","first-page":"1213629","DOI":"10.3389\/fimmu.2023.1213629","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Wang R, Wang X, et al. Impaired function of dendritic cells within the tumor microenvironment. Front Immunol. 2023;14:1213629.","journal-title":"Front Immunol"},{"issue":"10","key":"2923_CR26","doi-asserted-by":"publisher","first-page":"e13441","DOI":"10.1371\/journal.pone.0013441","volume":"5","author":"V Tjomsland","year":"2010","unstructured":"Tjomsland V, Sp\u00e5ngeus A, Sandstr\u00f6m P, Borch K, Messmer D, Larsson M. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS ONE. 2010;5(10):e13441.","journal-title":"PLoS ONE"},{"issue":"1","key":"2923_CR27","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41467-017-02186-9","volume":"8","author":"F Veglia","year":"2017","unstructured":"Veglia F, Tyurin VA, Mohammadyani D, et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun. 2017;8(1):2122.","journal-title":"Nat Commun"},{"issue":"15","key":"2923_CR28","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1158\/0008-5472.CAN-16-2212","volume":"77","author":"JA Kenkel","year":"2017","unstructured":"Kenkel JA, Tseng WW, Davidson MG, et al. An immunosuppressive dendritic cell subset accumulates at secondary sites and promotes metastasis in pancreatic cancer. Cancer Res. 2017;77(15):4158\u201370.","journal-title":"Cancer Res"},{"key":"2923_CR29","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.3389\/fimmu.2019.02876","volume":"10","author":"NC DeVito","year":"2019","unstructured":"DeVito NC, Plebanek MP, Theivanthiran B, Hanks BA. Role of tumor-mediated dendritic cell tolerization in immune evasion. Front Immunol. 2019;10:2876.","journal-title":"Front Immunol"},{"issue":"5","key":"2923_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00018-016-2317-8","volume":"74","author":"M Tang","year":"2017","unstructured":"Tang M, Diao J, Cattral MS. Molecular mechanisms involved in dendritic cell dysfunction in cancer. Cell Mol Life Sci. 2017;74(5):761\u201376.","journal-title":"Cell Mol Life Sci"},{"key":"2923_CR31","doi-asserted-by":"crossref","unstructured":"Gao C, Shen Q, Yin T. Cellular crosstalk mediating immune evasion in pancreatic cancer microenvironment. Ann Pancreat Cancer. 2019;2:13.","DOI":"10.21037\/apc.2019.06.04"},{"issue":"6527","key":"2923_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/375155a0","volume":"375","author":"Y Tanaka","year":"1995","unstructured":"Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human \u03b3\u03b4 T cells. Nature. 1995;375(6527):155\u20138.","journal-title":"Nature"},{"issue":"5","key":"2923_CR33","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","volume":"112","author":"J Zhu","year":"2008","unstructured":"Zhu J, Paul WE. CD4 T cells: Fates, functions, and faults. Blood. 2008;112(5):1557\u201369.","journal-title":"Blood"},{"issue":"1","key":"2923_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","volume":"32","author":"Y Chien","year":"2014","unstructured":"Chien Y, Meyer C, Bonneville M. \u03b3\u03b4 T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32(1):121\u201355.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2923_CR35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomata","year":"2023","unstructured":"Falcomata C, Baerthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D. Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Discov. 2023;13(2):278\u201397.","journal-title":"Cancer Discov"},{"issue":"1","key":"2923_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol Mech Dis. 2023;18(1):123\u201348.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"50","key":"2923_CR37","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci. 2013;110(50):20212\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"2923_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607\u201315.","journal-title":"Nat Med"},{"issue":"9","key":"2923_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","volume":"61","author":"MR Porembka","year":"2012","unstructured":"Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61(9):1373\u201385.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2923_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2923_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2923_CR42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u20139.","journal-title":"Nat Immunol"},{"key":"2923_CR43","doi-asserted-by":"publisher","first-page":"839893","DOI":"10.3389\/fcell.2022.839893","volume":"10","author":"R Wei","year":"2022","unstructured":"Wei R, Zhang H, Cao J, Qin D, Deng W, Li S. Type 1 T helper cell-based molecular subtypes and signature are associated with clinical outcome in pancreatic ductal adenocarcinoma. Front Cell Dev Biol. 2022;10:839893.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"2923_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ccr.2008.12.018","volume":"15","author":"M Kortylewski","year":"2009","unstructured":"Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;15(2):114\u201323.","journal-title":"Cancer Cell"},{"issue":"3","key":"2923_CR45","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20101876","volume":"208","author":"L De Monte","year":"2011","unstructured":"De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208(3):469\u201378.","journal-title":"J Exp Med"},{"key":"2923_CR46","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fimmu.2018.01044","volume":"9","author":"ED Foucher","year":"2018","unstructured":"Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment. Front Immunol. 2018;9:1044.","journal-title":"Front Immunol"},{"issue":"1","key":"2923_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1167\/iovs.02-0420","volume":"44","author":"A Leonardi","year":"2003","unstructured":"Leonardi A, Cortivo R, Fregona I, Plebani M, Secchi AG, Abatangelo G. Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2003;44(1):183\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"2923_CR48","doi-asserted-by":"publisher","first-page":"7424","DOI":"10.3390\/ijms12117424","volume":"12","author":"S He","year":"2011","unstructured":"He S, Fei M, Wu Y, et al. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci. 2011;12(11):7424\u201337.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2923_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ccr.2014.03.014","volume":"25","author":"F McAllister","year":"2014","unstructured":"McAllister F, Bailey JM, Alsina J, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 2014;25(5):621\u201337.","journal-title":"Cancer Cell"},{"issue":"7","key":"2923_CR50","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.4049\/jimmunol.0902609","volume":"185","author":"JL Gnerlich","year":"2010","unstructured":"Gnerlich JL, Mitchem JB, Weir JS, et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol. 2010;185(7):4063\u201371.","journal-title":"J Immunol"},{"issue":"1","key":"2923_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","volume":"24","author":"MT Anvar","year":"2024","unstructured":"Anvar MT, Rashidan K, Arsam N, et al. Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies? Cancer Cell Int. 2024;24(1):355.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"2923_CR52","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2923_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27(4):635\u201346.","journal-title":"Immunity"},{"issue":"3","key":"2923_CR54","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","volume":"20","author":"JE Jang","year":"2017","unstructured":"Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Cell Rep. 2017;20(3):558\u201371. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.062.","journal-title":"Cell Rep"},{"key":"2923_CR55","doi-asserted-by":"publisher","first-page":"108895","DOI":"10.1016\/j.intimp.2022.108895","volume":"108","author":"FN Shamohammadi","year":"2022","unstructured":"Shamohammadi FN, Yazdanifar M, Oraei M, et al. Controversial role of \u03b3\u03b4 T cells in pancreatic cancer. Int Immunopharmacol. 2022;108:108895.","journal-title":"Int Immunopharmacol"},{"key":"2923_CR56","doi-asserted-by":"crossref","unstructured":"Daley D, Zambirinis CP, Seifert L, et al. \u03b3\u03b4 T cells support pancreatic oncogenesis by restraining \u03b1\u03b2 T cell activation. Cell. 2016;166(6):1485\u20131499. e15.","DOI":"10.1016\/j.cell.2016.07.046"},{"issue":"33","key":"2923_CR57","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.3748\/wjg.v24.i33.3709","volume":"24","author":"K Wang","year":"2018","unstructured":"Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol. 2018;24(33):3709.","journal-title":"World J Gastroenterol"},{"key":"2923_CR58","doi-asserted-by":"publisher","first-page":"215868","DOI":"10.1016\/j.canlet.2022.215868","volume":"548","author":"Y Ma","year":"2022","unstructured":"Ma Y, Nikfarjam M, He H. The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. Cancer Lett. 2022;548:215868. https:\/\/doi.org\/10.1016\/j.canlet.2022.215868.","journal-title":"Cancer Lett"},{"issue":"18","key":"2923_CR59","doi-asserted-by":"publisher","first-page":"8778","DOI":"10.18632\/oncotarget.2398","volume":"5","author":"N Tyagi","year":"2014","unstructured":"Tyagi N, Bhardwaj A, Singh AP, McClellan S, Carter JE, Singh S. p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT-and ERK-dependent activation of NF-\u03baB pathway. Oncotarget. 2014;5(18):8778.","journal-title":"Oncotarget"},{"issue":"8","key":"2923_CR60","doi-asserted-by":"publisher","first-page":"14173","DOI":"10.18632\/oncotarget.13309","volume":"8","author":"K Thillai","year":"2016","unstructured":"Thillai K, Lam H, Sarker D, Wells CM. Deciphering the link between PI3K and PAK: an opportunity to target key pathways in pancreatic cancer? Oncotarget. 2016;8(8):14173.","journal-title":"Oncotarget"},{"issue":"34","key":"2923_CR61","doi-asserted-by":"publisher","first-page":"32115","DOI":"10.1074\/jbc.M100871200","volume":"276","author":"C Dan","year":"2001","unstructured":"Dan C, Kelly A, Bernard O, Minden A. Cytoskeletal changes regulated by the PAK4 serine\/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem. 2001;276(34):32115\u201321.","journal-title":"J Biol Chem"},{"issue":"4","key":"2923_CR62","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/path.4412","volume":"234","author":"W Zhou","year":"2014","unstructured":"Zhou W, Jubb AM, Lyle K, et al. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol. 2014;234(4):502\u201313.","journal-title":"J Pathol"},{"issue":"1","key":"2923_CR63","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1074\/jbc.M105732200","volume":"277","author":"MG Callow","year":"2002","unstructured":"Callow MG, Clairvoyant F, Zhu S, et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem. 2002;277(1):550\u20138.","journal-title":"J Biol Chem"},{"key":"2923_CR64","doi-asserted-by":"publisher","first-page":"104408","DOI":"10.1016\/j.cellimm.2021.104408","volume":"367","author":"A Na\u0457ja","year":"2021","unstructured":"Na\u0457ja A, Merhi M, Inchakalody V, et al. The role of PAK4 in the immune system and its potential implication in cancer immunotherapy. Cell Immunol. 2021;367:104408.","journal-title":"Cell Immunol"},{"issue":"1","key":"2923_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2172-10-15","volume":"10","author":"L Zhou","year":"2009","unstructured":"Zhou L, Yan C, Gieling RG, et al. Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated kinase-1. BMC Immunol. 2009;10(1):15.","journal-title":"BMC Immunol"},{"issue":"1","key":"2923_CR66","first-page":"5810465","volume":"2019","author":"R Xu","year":"2019","unstructured":"Xu R, Won JY, Kim CH, Kim DE, Yim H. Roles of the phosphorylation of transcriptional factors in epithelial\u2010mesenchymal transition. J Oncol. 2019;2019(1):5810465.","journal-title":"J Oncol"},{"issue":"1","key":"2923_CR67","doi-asserted-by":"publisher","first-page":"42575","DOI":"10.1038\/srep42575","volume":"7","author":"H King","year":"2017","unstructured":"King H, Thillai K, Whale A, et al. PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration. Sci Rep. 2017;7(1):42575. https:\/\/doi.org\/10.1038\/srep42575.","journal-title":"Sci Rep"},{"issue":"1","key":"2923_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s43018-019-0003-0","volume":"1","author":"G Abril-Rodriguez","year":"2020","unstructured":"Abril-Rodriguez G, Torrejon DY, Liu W, et al. PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer. 2020;1(1):46\u201358.","journal-title":"Nat Cancer"},{"issue":"3","key":"2923_CR69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4143\/crt.2014.054","volume":"47","author":"SU Moon","year":"2015","unstructured":"Moon SU, Kim JW, Sung JH, et al. p21-activated kinase 4 (PAK4) as a predictive marker of gemcitabine sensitivity in pancreatic cancer cell lines. Cancer Res Treat Off J Korean Cancer Assoc. 2015;47(3):501\u20138.","journal-title":"Cancer Res Treat Off J Korean Cancer Assoc"},{"issue":"2","key":"2923_CR70","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.canlet.2015.10.028","volume":"370","author":"N Tyagi","year":"2016","unstructured":"Tyagi N, Marimuthu S, Bhardwaj A, et al. p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. Cancer Lett. 2016;370(2):260\u20137.","journal-title":"Cancer Lett"},{"key":"2923_CR71","doi-asserted-by":"publisher","first-page":"1347683","DOI":"10.3389\/fimmu.2024.1347683","volume":"15","author":"H Yang","year":"2024","unstructured":"Yang H, Li Z, Zhu S, et al. Molecular mechanisms of pancreatic cancer liver metastasis: the role of PAK2. Front Immunol. 2024;15:1347683.","journal-title":"Front Immunol"},{"issue":"24","key":"2923_CR72","doi-asserted-by":"publisher","first-page":"13443","DOI":"10.3390\/ijms252413443","volume":"25","author":"M Wu","year":"2024","unstructured":"Wu M, Sarkar C, Guo B. Regulation of cancer metastasis by PAK2. Int J Mol Sci. 2024;25(24):13443.","journal-title":"Int J Mol Sci"},{"key":"2923_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2019.04.026","volume":"456","author":"HY Wu","year":"2019","unstructured":"Wu HY, Yang MC, Ding LY, Chen CS, Chu PC. p21-activated kinase 3 promotes cancer stem cell phenotypes through activating the Akt-GSK3\u03b2-\u03b2-catenin signaling pathway in pancreatic cancer cells. Cancer Lett. 2019;456:13\u201322.","journal-title":"Cancer Lett"},{"issue":"28","key":"2923_CR74","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1038\/onc.2009.119","volume":"28","author":"PR Molli","year":"2009","unstructured":"Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009;28(28):2545\u201355.","journal-title":"Oncogene"},{"key":"2923_CR75","doi-asserted-by":"publisher","first-page":"121263","DOI":"10.1016\/j.lfs.2022.121263","volume":"312","author":"L Tang","year":"2023","unstructured":"Tang L, Gao Y, Li T. Pan-cancer analysis identifies the immunological and prognostic role of PAK4. Life Sci. 2023;312:121263.","journal-title":"Life Sci"},{"issue":"1","key":"2923_CR76","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12920-024-01917-4","volume":"17","author":"L Tang","year":"2024","unstructured":"Tang L, Ye H, Chen L, Dong W, Hu X, Yu L. Tumorigenic role of Pak4 in ovarian cancer and its correlation with immune infiltration. BMC Med Genomics. 2024;17(1):148.","journal-title":"BMC Med Genomics"},{"issue":"10","key":"2923_CR77","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/2767-9764.CRC-21-0133","volume":"2","author":"G Abril-Rodriguez","year":"2022","unstructured":"Abril-Rodriguez G, Torrejon DY, Karin D, et al. Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade. Cancer Res Commun. 2022;2(10):1214\u201328.","journal-title":"Cancer Res Commun"},{"issue":"23","key":"2923_CR78","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/cells12232692","volume":"12","author":"A Ansardamavandi","year":"2023","unstructured":"Ansardamavandi A, Nikfarjam M, He H. PAK in pancreatic cancer-associated vasculature: implications for therapeutic response. Cells. 2023;12(23):2692.","journal-title":"Cells"},{"issue":"17","key":"2923_CR79","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3390\/cells13171444","volume":"13","author":"J Zhang","year":"2024","unstructured":"Zhang J, Song Y, Ahn AR, et al. PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients. Cells. 2024;13(17):1444.","journal-title":"Cells"},{"issue":"10","key":"2923_CR80","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/stmcls\/sxac050","volume":"40","author":"F Cheng","year":"2022","unstructured":"Cheng F, Li M, Thorne RF, et al. P21-activated kinase 4 Pak4 maintains embryonic stem cell pluripotency via Akt activation. Stem Cells. 2022;40(10):892\u2013905.","journal-title":"Stem Cells"},{"issue":"5","key":"2923_CR81","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19(5):287\u2013305.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2923_CR82","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49(6):1148-1161 e7.","journal-title":"Immunity"},{"issue":"1","key":"2923_CR83","doi-asserted-by":"publisher","first-page":"14092","DOI":"10.1038\/s41598-024-64126-0","volume":"14","author":"D Takatsuka","year":"2024","unstructured":"Takatsuka D, Tachinami H, Suzuki N, et al. PAK4 inhibition augments anti-tumour effect by immunomodulation in oral squamous cell carcinoma. Sci Rep. 2024;14(1):14092. https:\/\/doi.org\/10.1038\/s41598-024-64126-0.","journal-title":"Sci Rep"},{"issue":"5","key":"2923_CR84","doi-asserted-by":"publisher","first-page":"376","DOI":"10.34067\/KID.0000282019","volume":"1","author":"JF Trott","year":"2020","unstructured":"Trott JF, Aboud OA, McLaughlin B, et al. Anti-cancer activity of PAK4\/NAMPT inhibitor and programmed cell death protein-1 antibody in kidney cancer. Kidney360. 2020;1(5):376\u201388.","journal-title":"Kidney360"},{"issue":"1","key":"2923_CR85","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","volume":"2","author":"W Ma","year":"2021","unstructured":"Ma W, Wang Y, Zhang R, et al. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. Nat Cancer. 2021;2(1):83\u201397.","journal-title":"Nat Cancer"},{"key":"2923_CR86","doi-asserted-by":"publisher","first-page":"216034","DOI":"10.1016\/j.canlet.2022.216034","volume":"555","author":"S Su","year":"2023","unstructured":"Su S, You S, Wang Y, et al. PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration. Cancer Lett. 2023;555:216034.","journal-title":"Cancer Lett"},{"issue":"17","key":"2923_CR87","doi-asserted-by":"publisher","first-page":"8357","DOI":"10.3390\/ijms26178357","volume":"26","author":"A Ansardamavandi","year":"2025","unstructured":"Ansardamavandi A, Dumesny C, Ma Y, et al. P-21 Kinase 1 or 4 Knockout Stimulated Anti-Tumour Immunity Against Pancreatic Cancer by Enhancing Vascular Normalisation. Int J Mol Sci. 2025;26(17):8357.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2923_CR88","doi-asserted-by":"publisher","first-page":"H926","DOI":"10.1152\/ajpheart.00779.2008","volume":"295","author":"PG Frank","year":"2008","unstructured":"Frank PG, Lisanti MP. ICAM-1: role in inflammation and in the regulation of vascular permeability. Am J Physiol Heart Circ Physiol. 2008;295(3):H926\u20137.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"2923_CR89","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.bbamcr.2015.05.031","volume":"1853","author":"K Dammann","year":"2015","unstructured":"Dammann K, Khare V, Lang M, et al. PAK1 modulates a PPAR\u03b3\/NF-\u03baB cascade in intestinal inflammation. Biochim Biophys Acta BBA-Mol Cell Res. 2015;1853(10):2349\u201360.","journal-title":"Biochim Biophys Acta BBA-Mol Cell Res"},{"issue":"1","key":"2923_CR90","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12885-017-3432-0","volume":"17","author":"N Huynh","year":"2017","unstructured":"Huynh N, Wang K, Yim M, et al. Depletion of p21-activated kinase 1 up-regulates the immune system of APC\u2206 14\/+ mice and inhibits intestinal tumorigenesis. BMC Cancer. 2017;17(1):431.","journal-title":"BMC Cancer"},{"issue":"21","key":"2923_CR91","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.7150\/thno.46913","volume":"10","author":"D Yao","year":"2020","unstructured":"Yao D, Li C, Rajoka MSR, et al. P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer. Theranostics. 2020;10(21):9741.","journal-title":"Theranostics"},{"key":"2923_CR92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.020","volume":"472","author":"K Wang","year":"2020","unstructured":"Wang K, Zhan Y, Huynh N, et al. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Cancer Lett. 2020;472:8\u201318.","journal-title":"Cancer Lett"},{"issue":"8","key":"2923_CR93","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.3390\/ijms26083885","volume":"26","author":"T Lu","year":"2025","unstructured":"Lu T, Huo Z, Zhang Y, Li X. The role of the p21-activated kinase family in tumor immunity. Int J Mol Sci. 2025;26(8):3885.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2923_CR94","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/cancers11101527","volume":"11","author":"JH Kim","year":"2019","unstructured":"Kim JH, Choi HS, Kim SL, Lee DS. The PAK1-Stat3 signaling pathway activates IL-6 gene transcription and human breast cancer stem cell formation. Cancers. 2019;11(10):1527.","journal-title":"Cancers"},{"issue":"2","key":"2923_CR95","doi-asserted-by":"publisher","first-page":"e1637","DOI":"10.1038\/cddis.2015.2","volume":"6","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Liu H, Xu L, et al. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-\u03baB\/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015;6(2):e1637\u2013e1637.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2923_CR96","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1038\/bjc.2014.251","volume":"110","author":"H Nishio","year":"2014","unstructured":"Nishio H, Yaguchi T, Sugiyama J, et al. Immunosuppression through constitutively activated NF-\u03baB signalling in human ovarian cancer and its reversal by an NF-\u03baB inhibitor. Br J Cancer. 2014;110(12):2965\u201374.","journal-title":"Br J Cancer"},{"key":"2923_CR97","doi-asserted-by":"crossref","unstructured":"Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;16(1):38\u201347.","DOI":"10.1016\/j.smim.2014.01.008"},{"issue":"15","key":"2923_CR98","first-page":"3001","volume":"120","author":"A Weigert","year":"2012","unstructured":"Weigert A, Weichand B, Sekar D, et al. HIF-1\u03b1 is a negative regulator of plasmacytoid DC development in vitro and in vivo. Blood J Am Soc Hematol. 2012;120(15):3001\u20136.","journal-title":"Blood J Am Soc Hematol"},{"issue":"12","key":"2923_CR99","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.7150\/ijbs.83467","volume":"19","author":"CF Li","year":"2023","unstructured":"Li CF, Chan TC, Fang FM, Yu SC, Huang HY. PAK1 overexpression promotes myxofibrosarcoma angiogenesis through STAT5B-mediated CSF2 transactivation: clinical and therapeutic relevance of amplification and nuclear entry. Int J Biol Sci. 2023;19(12):3920.","journal-title":"Int J Biol Sci"},{"issue":"50","key":"2923_CR100","doi-asserted-by":"publisher","first-page":"39451","DOI":"10.1074\/jbc.M006150200","volume":"275","author":"R Bagheri-Yarmand","year":"2000","unstructured":"Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-\u03b21-mediated angiogenesis. J Biol Chem. 2000;275(50):39451\u20137.","journal-title":"J Biol Chem"},{"key":"2923_CR101","doi-asserted-by":"crossref","unstructured":"Murugan S, Gopinath P, Saravanan R, et al. Pak1 dysregulates pyruvate metabolism in PDAC cells by exerting a phosphorylation-mediated regulatory effect on PDHA1. J Biol Chem. 2025;301(4):108409.","DOI":"10.1016\/j.jbc.2025.108409"},{"issue":"8","key":"2923_CR102","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1111\/cas.14091","volume":"110","author":"J Long","year":"2019","unstructured":"Long J, Hu Z, Xue H, et al. Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway. Cancer Sci. 2019;110(8):2357\u201367.","journal-title":"Cancer Sci"},{"issue":"3","key":"2923_CR103","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409\u201316.","journal-title":"Ann Oncol"},{"issue":"1","key":"2923_CR104","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s13046-019-1407-5","volume":"38","author":"S Kim","year":"2019","unstructured":"Kim S, Jang JY, Koh J, et al. Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):462.","journal-title":"J Exp Clin Cancer Res"},{"key":"2923_CR105","doi-asserted-by":"publisher","first-page":"1189953","DOI":"10.3389\/fimmu.2023.1189953","volume":"14","author":"J Lin","year":"2023","unstructured":"Lin J, Fang W, Xiang Z, et al. Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion. Front Immunol. 2023;14:1189953.","journal-title":"Front Immunol"},{"key":"2923_CR106","doi-asserted-by":"publisher","first-page":"693215","DOI":"10.3389\/fcell.2021.693215","volume":"9","author":"R Qiu","year":"2021","unstructured":"Qiu R, Zhong Y, Li Q, Li Y, Fan H. Metabolic remodeling in glioma immune microenvironment: intercellular interactions distinct from peripheral tumors. Front Cell Dev Biol. 2021;9:693215.","journal-title":"Front Cell Dev Biol"},{"key":"2923_CR107","doi-asserted-by":"crossref","unstructured":"Kanemaru H, Mizukami Y, Kaneko A, et al. A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells. iScience. 2021;24(9):103067.","DOI":"10.1016\/j.isci.2021.103067"},{"issue":"16","key":"2923_CR108","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41388-020-1216-5","volume":"39","author":"TP Brown","year":"2020","unstructured":"Brown TP, Bhattacharjee P, Ramachandran S, et al. The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment. Oncogene. 2020;39(16):3292\u2013304.","journal-title":"Oncogene"},{"issue":"5","key":"2923_CR109","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12195-020-00652-x","volume":"13","author":"R Sangsuwan","year":"2020","unstructured":"Sangsuwan R, Thuamsang B, Pacifici N, et al. Lactate exposure promotes immunosuppressive phenotypes in innate immune cells. Cell Mol Bioeng. 2020;13(5):541\u201357.","journal-title":"Cell Mol Bioeng"},{"issue":"7","key":"2923_CR110","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1158\/0008-5472.CAN-17-1307","volume":"78","author":"N Caronni","year":"2018","unstructured":"Caronni N, Simoncello F, Stafetta F, et al. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Cancer Res. 2018;78(7):1685\u201399.","journal-title":"Cancer Res"},{"key":"2923_CR111","doi-asserted-by":"publisher","first-page":"613492","DOI":"10.3389\/fimmu.2021.613492","volume":"12","author":"X Peng","year":"2021","unstructured":"Peng X, He Y, Huang J, Tao Y, Liu S. Metabolism of dendritic cells in tumor microenvironment: for immunotherapy. Front Immunol. 2021;12:613492.","journal-title":"Front Immunol"},{"issue":"15","key":"2923_CR112","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2174\/13816128113199990486","volume":"20","author":"D Guo","year":"2014","unstructured":"Guo D, Hlavin Bell E, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des. 2014;20(15):2619\u201326.","journal-title":"Curr Pharm Des"},{"issue":"12","key":"2923_CR113","doi-asserted-by":"publisher","first-page":"158518","DOI":"10.1016\/j.bbalip.2019.158518","volume":"1864","author":"AV Bitorina","year":"2019","unstructured":"Bitorina AV, Oligschlaeger Y, Shiri-Sverdlov R, Theys J. Low profile high value target: the role of OxLDL in cancer. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(12):158518. https:\/\/doi.org\/10.1016\/j.bbalip.2019.158518.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"7","key":"2923_CR114","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161(7):1527\u201338. https:\/\/doi.org\/10.1016\/j.cell.2015.05.025.","journal-title":"Cell"},{"issue":"50","key":"2923_CR115","doi-asserted-by":"publisher","first-page":"e2412157121","DOI":"10.1073\/pnas.2412157121","volume":"121","author":"GP Lobel","year":"2024","unstructured":"Lobel GP, Han N, Molina Arocho WA, et al. Glutamine is critical for the maintenance of type 1 conventional dendritic cells in normal tissue and the tumor microenvironment. Proc Natl Acad Sci. 2024;121(50):e2412157121.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2923_CR116","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.devcel.2019.05.043","volume":"50","author":"SW Lee","year":"2019","unstructured":"Lee SW, Zhang Y, Jung M, Cruz N, Alas B, Commisso C. EGFR-Pak signaling selectively regulates glutamine deprivation-induced macropinocytosis. Dev Cell. 2019;50(3):381-392. e5.","journal-title":"Dev Cell"},{"issue":"1","key":"2923_CR117","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13046-015-0165-2","volume":"34","author":"S Cai","year":"2015","unstructured":"Cai S, Ye Z, Wang X, et al. Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion. J Exp Clin Cancer Res. 2015;34(1):48.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2923_CR118","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934-949. e16.","journal-title":"Cell"},{"issue":"1","key":"2923_CR119","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12964-024-01670-2","volume":"22","author":"Y Ma","year":"2024","unstructured":"Ma Y, Dumesny C, Dong L, et al. Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity. Cell Commun Signal. 2024;22(1):287. https:\/\/doi.org\/10.1186\/s12964-024-01670-2.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"2923_CR120","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/cancers17030511","volume":"17","author":"Y Ma","year":"2025","unstructured":"Ma Y, Dumesny C, Dong L, Ang CS, Nikfarjam M, He H. Knockout of p21-activated kinase 4 stimulates MHC I expression of pancreatic cancer cells via an autophagy-independent pathway. Cancers. 2025;17(3):511. https:\/\/doi.org\/10.3390\/cancers17030511.","journal-title":"Cancers"},{"issue":"7559","key":"2923_CR121","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135. https:\/\/doi.org\/10.1038\/nature14404.","journal-title":"Nature"},{"issue":"1","key":"2923_CR122","doi-asserted-by":"publisher","first-page":"1809947","DOI":"10.1080\/2162402X.2020.1809947","volume":"9","author":"C Wang","year":"2020","unstructured":"Wang C, Yan J, Yin P, et al. \u03b2-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer. Oncoimmunology. 2020;9(1):1809947.","journal-title":"Oncoimmunology"},{"issue":"22","key":"2923_CR123","doi-asserted-by":"publisher","first-page":"11490","DOI":"10.18632\/oncotarget.2571","volume":"5","author":"A Bhardwaj","year":"2014","unstructured":"Bhardwaj A, Srivastava SK, Singh S, et al. CXCL12\/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget. 2014;5(22):11490.","journal-title":"Oncotarget"},{"key":"2923_CR124","doi-asserted-by":"publisher","first-page":"117534","DOI":"10.1016\/j.lfs.2020.117534","volume":"249","author":"K Mortezaee","year":"2020","unstructured":"Mortezaee K. CXCL12\/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis. Life Sci. 2020;249:117534.","journal-title":"Life Sci"},{"issue":"20","key":"2923_CR125","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1038\/s41388-019-0677-x","volume":"38","author":"P Dong","year":"2019","unstructured":"Dong P, Xiong Y, Yu J, et al. Correction: Control of PD-L1 expression by miR-140\/142\/340\/383 and oncogenic activation of the OCT4\u2013miR-18a pathway in cervical cancer. Oncogene. 2019;38(20):3972.","journal-title":"Oncogene"},{"issue":"12","key":"2923_CR126","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri.2016.99","volume":"16","author":"C Mu\u00f1oz-Fontela","year":"2016","unstructured":"Mu\u00f1oz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol. 2016;16(12):741\u201350.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2923_CR127","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.biocel.2010.03.004","volume":"42","author":"V Olive","year":"2010","unstructured":"Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol. 2010;42(8):1348\u201354.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"2923_CR128","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41420-025-02427-7","volume":"11","author":"L Yao","year":"2025","unstructured":"Yao L, Wang H, Liu Y, et al. Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment. Cell Death Discov. 2025;11(1):136.","journal-title":"Cell Death Discov"},{"issue":"10","key":"2923_CR129","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.bbamcr.2008.04.016","volume":"1783","author":"H He","year":"2008","unstructured":"He H, Shulkes A, Baldwin GS. PAK1 interacts with \u03b2-catenin and is required for the regulation of the \u03b2-catenin signalling pathway by gastrins. Biochim Biophys Acta BBA Mol Cell Res. 2008;1783(10):1943\u201354.","journal-title":"Biochim Biophys Acta BBA Mol Cell Res"},{"issue":"2","key":"2923_CR130","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/cco.2019.03.02","volume":"8","author":"YF Zhang","year":"2019","unstructured":"Zhang YF, Jiang SH, Hu LP, et al. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Chin Clin Oncol. 2019;8(2):18\u201318.","journal-title":"Chin Clin Oncol"},{"key":"2923_CR131","doi-asserted-by":"publisher","first-page":"102843","DOI":"10.1016\/j.ctrv.2024.102843","volume":"131","author":"S Ielpo","year":"2024","unstructured":"Ielpo S, Barberini F, Moghaddam FD, et al. Crosstalk and communication of cancer-associated fibroblasts with natural killer and dendritic cells: New frontiers and unveiled opportunities for cancer immunotherapy. Cancer Treat Rev. 2024;131:102843.","journal-title":"Cancer Treat Rev"},{"key":"2923_CR132","doi-asserted-by":"crossref","unstructured":"Cao C, Xu M, Wei Y, et al. CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2\/STAT3 pathway. Cell Genom. 2024;4(10):100659.","DOI":"10.1016\/j.xgen.2024.100659"},{"key":"2923_CR133","doi-asserted-by":"publisher","first-page":"154820","DOI":"10.1016\/j.prp.2023.154820","volume":"251","author":"JS Pyo","year":"2023","unstructured":"Pyo JS, Min KW, Oh IH, Lim DH, Son BK. Clinicopathological significance and the associated signaling pathway of p21-activated kinase 1 (PAK1) in colorectal cancer. Pathol Res Pract. 2023;251:154820.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"2923_CR134","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bbrc.2020.03.054","volume":"526","author":"S Jiang","year":"2020","unstructured":"Jiang S, Gao Y, Yu QH, et al. P-21-activated kinase 1 contributes to tumor angiogenesis upon photodynamic therapy via the HIF-1\u03b1\/VEGF pathway. Biochem Biophys Res Commun. 2020;526(1):98\u2013104.","journal-title":"Biochem Biophys Res Commun"},{"key":"2923_CR135","doi-asserted-by":"publisher","first-page":"1549276","DOI":"10.3389\/fimmu.2025.1549276","volume":"16","author":"S Shi","year":"2025","unstructured":"Shi S, Ou X, Liu C, Wen H, Ke J. Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment. Front Immunol. 2025;16:1549276.","journal-title":"Front Immunol"},{"issue":"9","key":"2923_CR136","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3390\/cancers12092403","volume":"12","author":"S Burgdorf","year":"2020","unstructured":"Burgdorf S, Porubsky S, Marx A, Popovic ZV. Cancer acidity and hypertonicity contribute to dysfunction of tumor-associated dendritic cells: potential impact on antigen cross-presentation machinery. Cancers. 2020;12(9):2403.","journal-title":"Cancers"},{"issue":"12","key":"2923_CR137","doi-asserted-by":"publisher","first-page":"e26744","DOI":"10.4161\/onci.26744","volume":"2","author":"A Nasi","year":"2013","unstructured":"Nasi A, Rethi B. Disarmed by density: a glycolytic break for immunostimulatory dendritic cells? Oncoimmunology. 2013;2(12):e26744.","journal-title":"Oncoimmunology"},{"issue":"4","key":"2923_CR138","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43(4):665\u201379.","journal-title":"Cancer Cell"},{"key":"2923_CR139","doi-asserted-by":"crossref","unstructured":"Pail O, Lin MJ, Anagnostou T, Brown BD, Brody JD. Cancer vaccines and the future of immunotherapy. Lancet. 2025;406(10499):189\u2013202.","DOI":"10.1016\/S0140-6736(25)00553-7"},{"issue":"2","key":"2923_CR140","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122\u201339.","journal-title":"Trends Cancer"},{"issue":"17","key":"2923_CR141","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1200\/JCO.22.02575","volume":"41","author":"GV Long","year":"2023","unstructured":"Long GV, Menzies AM, Scolyer RA. Neoadjuvant checkpoint immunotherapy and melanoma: the time is now. J Clin Oncol. 2023;41(17):3236\u201348.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2923_CR142","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.trecan.2024.05.001","volume":"10","author":"M Singh","year":"2024","unstructured":"Singh M, Morris VK, Bandey IN, Hong DS, Kopetz S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer. 2024;10(7):598\u2013609.","journal-title":"Trends Cancer"},{"issue":"8062","key":"2923_CR143","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen Y, Bai X, Zhang Q, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature. 2025;641(8062):503\u201311.","journal-title":"Nature"},{"issue":"10","key":"2923_CR144","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(10):1431\u20138.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2923_CR145","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878\u201385.","journal-title":"Nat Med"},{"issue":"1","key":"2923_CR146","first-page":"62","volume":"4","author":"P Gulhati","year":"2023","unstructured":"Gulhati P, Schalck A, Jiang S, et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer. 2023;4(1):62\u201380.","journal-title":"Nat Cancer"},{"issue":"24","key":"2923_CR147","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1158\/0008-5472.CAN-24-0830","volume":"84","author":"K Oyama","year":"2024","unstructured":"Oyama K, Nakata K, Tsutsumi C, et al. Combined autophagy Inhibition and dendritic cell recruitment induces antitumor immunity and enhances immune checkpoint Blockade sensitivity in pancreatic cancer. Cancer Res. 2024;84(24):4214\u201332.","journal-title":"Cancer Res"},{"issue":"2","key":"2923_CR148","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00432-020-03463-9","volume":"147","author":"Z Hou","year":"2021","unstructured":"Hou Z, Pan Y, Fei Q, et al. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. J Cancer Res Clin Oncol. 2021;147(2):517\u201331.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"B","key":"2923_CR149","first-page":"955","volume":"6","author":"AJ Lepisto","year":"2008","unstructured":"Lepisto AJ, Moser AJ, Zeh H, et al. A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955.","journal-title":"Cancer Ther"},{"issue":"16","key":"2923_CR150","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-14-0314","volume":"20","author":"S Koido","year":"2014","unstructured":"Koido S, Homma S, Okamoto M, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms\u2019 Tumor 1 (WT1)\u2013specific MHC class I\/II\u2013restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014;20(16):4228\u201339.","journal-title":"Clin Cancer Res"},{"key":"2923_CR151","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2022.03.015","volume":"169","author":"SP Lau","year":"2022","unstructured":"Lau SP, Klaase L, Vink M, et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study. Eur J Cancer. 2022;169:20\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.015.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2923_CR152","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-017-0459-2","volume":"10","author":"S Mehrotra","year":"2017","unstructured":"Mehrotra S, Britten CD, Chin S, et al. Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017;10(1):82.","journal-title":"J Hematol Oncol"},{"key":"2923_CR153","doi-asserted-by":"crossref","unstructured":"Kandalaft LE. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma\u2014A Proof of Antigen Discovery Feasibility in Three Patients. Front Immunol. 2019;10:1832.","DOI":"10.3389\/fimmu.2019.01832"},{"issue":"21","key":"2923_CR154","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi C, Zhang P, Liu C, et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J Clin Oncol. 2024;42(21):2565\u201377.","journal-title":"J Clin Oncol"},{"key":"2923_CR155","doi-asserted-by":"crossref","unstructured":"Aznar MA, Good CR, Barber-Rotenberg JS, et al. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med. 2025;6(9):102301.","DOI":"10.1016\/j.xcrm.2025.102301"},{"issue":"7","key":"2923_CR156","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00262-025-04039-7","volume":"74","author":"MA Aboalela","year":"2025","unstructured":"Aboalela MA, Abdelmoneim M, Matsumura S, et al. Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression. Cancer Immunol Immunother. 2025;74(7):202.","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"2923_CR157","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"2923_CR158","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3892\/ijo.2023.5534","volume":"63","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yang S, Wan L, Ling W, Chen H, Wang J. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy. Int J Oncol. 2023;63(1):86.","journal-title":"Int J Oncol"},{"key":"2923_CR159","doi-asserted-by":"crossref","unstructured":"Cheng B, Lv J, Xiao Y, Song C, Chen J, Shao C. Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020\u20132024). Eur J Med Chem. 2025;283:117141.","DOI":"10.1016\/j.ejmech.2024.117141"},{"issue":"8","key":"2923_CR160","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828\u201333.","journal-title":"J Immunother"},{"issue":"26","key":"2923_CR161","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of Anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1200694.","journal-title":"N Engl J Med"},{"issue":"19","key":"2923_CR162","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286\u201393.","journal-title":"Clin Cancer Res"},{"key":"2923_CR163","doi-asserted-by":"publisher","first-page":"e923803-1","DOI":"10.12659\/AJCR.923803","volume":"21","author":"NR Patil","year":"2020","unstructured":"Patil NR, Khan GN. Exceptional response to a single cycle of immunotherapy in a Lynch syndrome patient with metastatic pancreatic adenocarcinoma. Am J Case Rep. 2020;21:e923803-1.","journal-title":"Am J Case Rep"},{"key":"2923_CR164","doi-asserted-by":"crossref","unstructured":"Wainberg ZA, Weekes CD, Furqan M, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025;31(11):3648\u201353 .","DOI":"10.1038\/s41591-025-03876-4"},{"issue":"1","key":"2923_CR165","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","volume":"18","author":"Y Hirooka","year":"2018","unstructured":"Hirooka Y, Kasuya H, Ishikawa T, et al. A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer. 2018;18(1):596.","journal-title":"BMC Cancer"},{"issue":"26","key":"2923_CR166","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.23.02585","volume":"42","author":"FR van \u2018t Land","year":"2024","unstructured":"van \u2018t Land FR, Willemsen M, Bezemer K, et al. Dendritic cell\u2013based immunotherapy in patients with resected pancreatic cancer. J Clin Oncol. 2024;42(26):3083\u201393.","journal-title":"J Clin Oncol"},{"issue":"12_Supplement","key":"2923_CR167","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1158\/1538-7445.AM2022-4178","volume":"82","author":"S Su","year":"2022","unstructured":"Su S, You S, Wang Y, Tamukong P, Grasso CS, Kim HL. PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer. Cancer Res. 2022;82(12_Supplement):4178\u20134178.","journal-title":"Cancer Res"},{"issue":"6703","key":"2923_CR168","doi-asserted-by":"publisher","first-page":"eadh4567","DOI":"10.1126\/science.adh4567","volume":"384","author":"KK Mahadevan","year":"2024","unstructured":"Mahadevan KK, Dyevoich AM, Chen Y, et al. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science. 2024;384(6703):eadh4567. https:\/\/doi.org\/10.1126\/science.adh4567.","journal-title":"Science"},{"issue":"21","key":"2923_CR169","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-24-3086","volume":"31","author":"S Wang","year":"2025","unstructured":"Wang S, Yu G, Dai Y, et al. IND-enabling studies for a TCR-T targeting a pancreatic cancer KRASG12V mutation. Clin Cancer Res. 2025;31(21):4557\u201370.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2923_CR170","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-016-0164-7","volume":"4","author":"M Hall","year":"2016","unstructured":"Hall M, Liu H, Malafa M, et al. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016;4(1):61.","journal-title":"J Immunother Cancer"},{"issue":"22","key":"2923_CR171","first-page":"1806","volume":"14","author":"A Ansardamavandi","year":"2025","unstructured":"Ansardamavandi A, Dumesny C, Ellis S, Ang CS, Nikfarjam M, He H. Targeting PAK1 or PAK4 uncovers different mechanisms of vascular reprogramming in pancreatic cancer. Cells (Basel). 2025;14(22):1806.","journal-title":"Cells (Basel)"},{"issue":"21","key":"2923_CR172","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.3390\/cancers17213434","volume":"17","author":"A Ansardamavandi","year":"2025","unstructured":"Ansardamavandi A, Dumesny C, Ma Y, et al. The effects of PAK-regulated tumour vasculature on gemcitabine response of pancreatic cancer. Cancers. 2025;17(21):3434.","journal-title":"Cancers"},{"key":"2923_CR173","doi-asserted-by":"crossref","unstructured":"Xu S, Ma B, Jian Y, et al. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. EBioMedicine. 2024;104:105162.","DOI":"10.1016\/j.ebiom.2024.105162"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02923-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02923-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02923-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:06:30Z","timestamp":1783483590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02923-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":173,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2923"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02923-y","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"393"}}